Qiagen QCI Interpret One Software; QiaSeq Pan-Cancer Multimodal Panel; and QiaSeq Targeted Methyl Panel

Qiagen launched multiple new products for genomic variation analysis in connection with the virtual 2020 American Society of Clinical Oncology annual meeting.

Qiagen's new QCI Interpret One software joins the company's Qiagen Clinical Insights portfolio, and provides variant- and disease-specific evidence for every variant in any somatic panel, backing each classification with the latest peer-reviewed publications, oncologist-reviewed interpretation summaries, and "expert second opinions," the company said. The new product combines the former N-f-One interpretation summaries with Qiagen's QCI Interpret structured variant interpretation database, the company noted.

Meanwhile, the new QiaSeq Pan-cancer Multimodal panel enables the consolidation of two separate next-generation sequencing-based DNA and RNA variant profiling workflows into one. It also enables scalable and parallel integration of up to thousands of targets in one enrichment step in a single tube, Qiagen said. Ideal for comprehensive genomic profiling and biomarker discovery, this 1.44-Mb panel consists of more than 600 target genes and fusions involved in the onset, progression, and treatment response across different cancer types, as well as microsatellite instability markers. Qiagen said the panel has a one-day turnaround time.

Finally, the new QiaSeq Targeted Methyl panels provide NGS-based targeted methylation analysis with a one-day turnaround time using the company's proprietary single primer extension technology. Qiagen offers predesigned panels for breast and colorectal cancer, as well as rapid, online custom design capabilities to create tailored panels for customer-specific applications. The company expects to launch immuno-oncology and T-cell infiltration applications later in 2020.